BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 36996802)

  • 1. Myeloid Proliferations Associated with Down Syndrome: Clinicopathologic Characteristics of Forty Cases from Five Large Academic Institutions.
    van den Akker TA; Liu YC; Liu H; Chapman J; Levine JM; Weinberg OK; Geyer JT
    Pathobiology; 2024; 91(1):89-98. PubMed ID: 36996802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Myeloid proliferations related to Down syndrome].
    Hasegawa D
    Rinsho Ketsueki; 2019; 60(9):1299-1307. PubMed ID: 31597856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in the understanding of transient abnormal myelopoiesis in Down syndrome.
    Watanabe K
    Pediatr Int; 2019 Mar; 61(3):222-229. PubMed ID: 30593694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transient Abnormal Myelopoiesis and AML in Down Syndrome: an Update.
    Bhatnagar N; Nizery L; Tunstall O; Vyas P; Roberts I
    Curr Hematol Malig Rep; 2016 Oct; 11(5):333-41. PubMed ID: 27510823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PRAME immunohistochemical staining in transient abnormal myelopoiesis and myeloid leukemia associated with Down syndrome.
    Chisholm KM; Rivetta CV; Heerema-McKenney A
    Ann Clin Lab Sci; 2015; 45(2):121-7. PubMed ID: 25887863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A sensitive and inexpensive high-resolution melting-based testing algorithm for diagnosis of transient abnormal myelopoiesis and myeloid leukemia of Down syndrome.
    Camargo R; de Castro Moreira Dos Santos A; Cândido Guido B; Lemos Mendanha Cavalcante L; Silva Dias AC; Mendonça de Pontes R; Magalhães Furtado F; Feitosa Salviano C; Tiziani V; Martins Córdoba JC; Quezado Magalhães IM
    Pediatr Blood Cancer; 2022 Nov; 69(11):e29866. PubMed ID: 35731576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct GATA1 Point Mutations in Monozygotic Twins With Down Syndrome and Transient Abnormal Myelopoiesis From a Triplet Pregnancy: A Case Report and Review of Literature.
    Yin L; Lovell MA; Wilson ML; Wei Q; Liang X
    Am J Clin Pathol; 2016 Dec; 146(6):753-759. PubMed ID: 28028114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GATA1 mutations in a cohort of Malaysian children with Down syndrome-associated myeloid disorder.
    Lum SH; Choong SS; Krishnan S; Mohamed Z; Ariffin H
    Singapore Med J; 2016 Jun; 57(6):320-4. PubMed ID: 27353457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical, cytogenetic, and molecular analyses of 17 neonates with transient abnormal myelopoiesis and nonconstitutional trisomy 21.
    Yuzawa K; Terui K; Toki T; Kanezaki R; Kobayashi A; Sato T; Kamio T; Kudo K; Sasaki S; Endo M; Ozono S; Nomura K; Ito E
    Pediatr Blood Cancer; 2020 Apr; 67(4):e28188. PubMed ID: 32020774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hematological disorders in children with Down syndrome.
    Triarico S; Trombatore G; Capozza MA; Romano A; Mastrangelo S; Attinà G; Maurizi P; Ruggiero A
    Expert Rev Hematol; 2022 Feb; 15(2):127-135. PubMed ID: 35184659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete blood count differences in a cohort of Down syndrome neonates with transient abnormal myelopoiesis screened for GATA1 pathogenic variants.
    Orozco-Vela M; Corona-Rivera A; Cruz-Osorio RM; Mendoza-Maldonado L; Márquez-Mora A; Barba-Barba CC; Peña-Padilla C; Baldomero-López A; Bobadilla-Morales L; Corona-Rivera JR
    Am J Med Genet A; 2020 Sep; 182(9):2085-2093. PubMed ID: 32681702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leukemogenesis in infants and young children with trisomy 21.
    Roberts I
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):1-8. PubMed ID: 36485097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling Down Syndrome Myeloid Leukemia by Sequential Introduction of
    Barwe SP; Sebastian A; Sidhu I; Kolb EA; Gopalakrishnapillai A
    Cells; 2022 Feb; 11(4):. PubMed ID: 35203280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biology and management of transient abnormal myelopoiesis (TAM) in children with Down syndrome.
    Roy A; Roberts I; Vyas P
    Semin Fetal Neonatal Med; 2012 Aug; 17(4):196-201. PubMed ID: 22421527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transient abnormal myelopoiesis of a newborn not associated with chromosome 21 abnormalities or GATA1 mutations.
    Nakashima MO; Shetty S; Chicka M; Flagg A; Eng C; Cotta CV
    Pediatr Blood Cancer; 2015 Feb; 62(2):353-355. PubMed ID: 25175265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution of myeloid leukemia in children with Down syndrome.
    Saida S
    Int J Hematol; 2016 Apr; 103(4):365-72. PubMed ID: 26910243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clonal selection in xenografted TAM recapitulates the evolutionary process of myeloid leukemia in Down syndrome.
    Saida S; Watanabe K; Sato-Otsubo A; Terui K; Yoshida K; Okuno Y; Toki T; Wang R; Shiraishi Y; Miyano S; Kato I; Morishima T; Fujino H; Umeda K; Hiramatsu H; Adachi S; Ito E; Ogawa S; Ito M; Nakahata T; Heike T
    Blood; 2013 May; 121(21):4377-87. PubMed ID: 23482930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The paradox of Myeloid Leukemia associated with Down syndrome.
    Gupte A; Al-Antary ET; Edwards H; Ravindranath Y; Ge Y; Taub JW
    Biochem Pharmacol; 2022 Jul; 201():115046. PubMed ID: 35483417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome.
    Labuhn M; Perkins K; Matzk S; Varghese L; Garnett C; Papaemmanuil E; Metzner M; Kennedy A; Amstislavskiy V; Risch T; Bhayadia R; Samulowski D; Hernandez DC; Stoilova B; Iotchkova V; Oppermann U; Scheer C; Yoshida K; Schwarzer A; Taub JW; Crispino JD; Weiss MJ; Hayashi Y; Taga T; Ito E; Ogawa S; Reinhardt D; Yaspo ML; Campbell PJ; Roberts I; Constantinescu SN; Vyas P; Heckl D; Klusmann JH
    Cancer Cell; 2019 Aug; 36(2):123-138.e10. PubMed ID: 31303423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recommendations for Diagnosis and Treatment of Children with Transient Abnormal Myelopoiesis (TAM) and Myeloid Leukemia in Down Syndrome (ML-DS).
    Al-Kershi S; Golnik R; Flasinski M; Waack K; Rasche M; Creutzig U; Dworzak M; Reinhardt D; Klusmann JH
    Klin Padiatr; 2021 Nov; 233(6):267-277. PubMed ID: 34407551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.